Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | CCKBR | P32239 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2067823 | 0.99 | CCNC (0.47) | CCNCCDK8IRAK4USP30NPC1 | |
| Glasdegib SCHEMBL24503991 | 0.91 | EPHX1 (0.45) | USP30NPC1RAB9APDPK1SMN1; SMN2 | |
| Glasdegib SCHEMBL18184932 | 0.91 | EPHX1 (0.45) | USP30NPC1RAB9APDPK1SMN1; SMN2 | |
| Glasdegib SCHEMBL2068480 | 0.91 | EPHX1 (0.45) | USP30NPC1RAB9APDPK1SMN1; SMN2 | |
| Glasdegib SCHEMBL27100349 | 0.91 | EPHX1 (0.45) | USP30NPC1RAB9APDPK1SMN1; SMN2 | |
| Glasdegib SCHEMBL29359708 | 0.91 | EPHX1 (0.45) | USP30NPC1RAB9APDPK1SMN1; SMN2 | |
| Glasdegib SCHEMBL22104131 | 0.91 | EPHX1 (0.45) | USP30NPC1RAB9APDPK1SMN1; SMN2 | |
| Glasdegib SCHEMBL2068016 | 0.90 | EPHX1 (0.44) | USP30NPC1RAB9APDPK1SMN1; SMN2 | |
| Glasdegib SCHEMBL29362720 | 0.90 | EPHX1 (0.44) | USP30NPC1RAB9APDPK1SMN1; SMN2 | |
| SCHEMBL2068332 | 0.88 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170860-B9 | BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-2170860-B1 | BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2016-11-02 | — | — | EP | disclosed |
| US-8431597-B2 | Benzimidazole derivatives | PFIZER INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431597-B2 | Benzimidazole derivatives | PFIZER INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431597-B2 | Benzimidazole derivatives | PFIZER INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120157495-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157495-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157495-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2012-06-21 | — | — | US | disclosed |
| US-8148401-B2 | Benzimidazole derivatives | PFIZER INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148401-B2 | Benzimidazole derivatives | PFIZER INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148401-B2 | Benzimidazole derivatives | PFIZER INC. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-2170860-A2 | BENZIMIDAZOLE DERIVATIVES | Pfizer Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009004427-A2 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2009-01-01 | — | — | US | disclosed |
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2009-01-01 | — | — | US | disclosed |
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | BOD1L1, H1-3, BRIX1 | CCNC 162/4885CDK8 1590/4885IRAK4 2231/4885 |
| US-20120157495-A1 | BENZIMIDAZOLE DERIVATIVES | BOD1L1, H1-3, BRIX1 | CCNC 162/4885CDK8 1590/4885IRAK4 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.